Trials / Completed
CompletedNCT00216749
Efficacy and Safety of Cilostazol for the Indication of CSPS
Post Marketing Surveillance of Efficacy and Safety of Cilostazol for the Indication of CSPS
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 650 (actual)
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, open-label, prospective study of cilostazol use for prevention of recurrence in patients with cerebral infarction.
Detailed description
This is a multicenter, open-label, prospective study of cilostazol use to prevention of recurrence in patients with cerebral infarction. Qualified patients will be treated with cilostazol by physician's assessment. This study will be continued for 4 years. More than 600 patients for 4 years.
Conditions
Timeline
- Start date
- 2003-12-01
- Primary completion
- 2007-10-01
- Completion
- 2007-10-01
- First posted
- 2005-09-22
- Last updated
- 2009-12-17
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT00216749. Inclusion in this directory is not an endorsement.